Marketing approvals for generic drugs may soon be delinked from their patent status in India. This comes as a result of long-standing demand from India’s pharmaceutical industry, which depends heavily on the sale of generic drugs.
India to delink marketing authorisation and patent status
Home/Policies & Legislation
|
Posted 07/01/2011
0
Post your comment
The health ministry is planning to remove a question on the patent status of a drug from the form that medicine companies fill in when applying to the Drug Controller General of India (DCGI) for regulatory approval, a ministry official said.
The proposal follows a meeting in Mumbai, India, in November 2010 between Indian drugmakers and Health Minister Ghulam Nabi Azad.
If deleted, the DCGI will issue approvals only on the grounds of drug quality and efficacy.
The issue will be taken up at the next Drug Testing Advisory Board meeting.
Source: Livemint
Guidelines
US guidance to remove biosimilar comparative efficacy studies
New guidance for biologicals in Pakistan and Hong Kong’s independent drug regulatory authority
Related content
EU accepts results from FDA GMP inspections for sites outside the US
Home/Policies & Legislation Posted 27/01/2026
WHO to remove animal tests and establish 17 reference standards for biologicals
Home/Policies & Legislation Posted 07/01/2026
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment